Dr. Boland brings over 30 years of experience in cellular therapies, regenerative medicine, and medical devices. He holds a Ph.D. in Biomedical Engineering from Virginia Commonwealth University and a B.S. in Biomedical Engineering from Marquette University.
Gene’s extensive career includes leadership roles at Longeveron, Inc. AmplifyBio, Talaris Therapeutics, Techshot, and the Cardiovascular Innovation Institute. At Longeveron, he serves as Vice President of Quality, where he is leading Quality Assurance and Quality Control under GMP and GCP standards. Gene aids cross-functional teams, including R&D, Manufacturing, Regulatory Affairs, and Clinical Operations, to ensure alignment and integration of quality initiatives.
Gene’s expertise also extends to implementing electronic Quality Management Systems, developing quality system documentation, and managing CDMO contracts. He has a proven track record of leading high-performing quality teams and driving continuous process improvement. His technical skills include stem cell isolation, TCR and CAR-T cell therapies, and various biochemical and molecular assays.
In his new role at Longeveron, Gene will oversee our Quality Assurance (QA) and Quality Control (QC) functions, ensuring the highest standards of quality and compliance across all aspects of our cell therapy drug development and manufacturing processes. He will be instrumental in developing and implementing comprehensive quality systems and processes to support the BLA submission and commercialization of our cell therapy products.
Dr. Boland first began working with salmon derived proteins in graduate school and continued that research effort to develop a cellularized vascular graft supported by the Department of Defense as well as an orthopedic effort to develop a self-assembled muscle-tendon construct for volumetric muscle loss. His Regenerative Medicine division at University of Louisville continued to focus on biohybrids and cell therapies in cardiovascular and skeletomuscular injuries and diseases. While at Techshot, he led a collaborative team that built and managed a 3D Bioprinter and Bioreactor platform aboard the International Space Station. This work included developing custom biologically derived inks and an automated processes for creating and culturing therapeutics iPSCs (allo- and autologous) to further differentiate into cardiovascular and skeletomuscular lineages.